GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18
- Conditions
- Infections, Papillomavirus
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 770
- Registration Number
- NCT00169494
- Locations
- 🇷🇺
GSK Investigational Site, Volgograd, Russian Federation
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 384
- Registration Number
- NCT00158860
- Locations
- 🇨🇱
GSK Investigational Site, Santiago, Región Metro De Santiago, Chile
GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol
- Conditions
- DyslipidaemiasDyslipidaemia
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 424
- Registration Number
- NCT00158899
- Locations
- 🇸🇪
GSK Investigational Site, Malmö, Sweden
A Study To Compare The Effects Of The Infusion Of A Sepsis Drug Between Healthy Adults And Adults With Damaged Livers
- Conditions
- Sepsis
- Interventions
- Drug: Intravenous GR270773 - Phospholipid emulsion
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00158769
- Locations
- 🇸🇰
GSK Investigational Site, Bratislava, Slovakia
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT00158782
- Locations
- 🇳🇱
GSK Investigational Site, Rotterdam, Netherlands
Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Radiation: Radiation therapy
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT00158886
- Locations
- 🇺🇸
GSK Investigational Site, Tampa, Florida, United States
Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine
- Conditions
- Haemophilus Influenzae Type b Disease
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 454
- Registration Number
- NCT00158795
- Locations
- 🇨🇳
GSK Investigational Site, Nanning, Guangxi, China
Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects
- Conditions
- Sedation
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 224
- Registration Number
- NCT00158873
- Locations
- 🇳🇱
GSK Investigational Site, Zwolle, Netherlands
Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications
- Conditions
- Asthma
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT00158834
- Locations
- 🇳🇱
GSK Investigational Site, Zwolle, Netherlands
Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths
- Conditions
- Hepatitis BProphylaxis of DiphtheriaTetanusHib DiseasePertussis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 175
- Registration Number
- NCT00158808
- Locations
- 🇵🇭
GSK Investigational Site, Muntinlupa, Philippines